Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.
AffiliationMédecins sans Frontières-Holland, P.O. Box 10014, 1001 EA Amsterdam, The Netherlands. firstname.lastname@example.org
MetadataShow full item record
AbstractWe evaluated generic sodium stibogluconate (SSG) (International Dispensary Association, Amsterdam) versus Pentostam (sodium stibogluconate, GlaxoWellcome, London) under field conditions in Ethiopian patients with visceral leishmaniasis (VL; kala-azar). The 199 patients were randomly assigned to Pentostam (n = 104) or SSG (n = 95) in 1998/99; both drugs were given at 20 mg/kg intra-muscularly for 30 days. A clinical cure after 30-days treatment was achieved in 70.2% (Pentostam) and 81.1% (SSG). There were no significant differences between the 2 drugs for the following parameters: frequency of intercurrent events (vomiting, diarrhoea, bleeding or pneumonia) or main outcome (death during treatment and death after 6-month follow-up; relapse or post kala-azar dermal leishmaniasis at 6-months follow-up). Twenty-seven patients had confirmed co-infection with HIV. On admission, HIV co-infected VL patients were clinically indistinguishable from HIV-negative VL patients. The HIV co-infected VL patients had a higher mortality during treatment (33.3% vs 3.6%). At 6-month follow-up, HIV-positive patients had a higher relapse rate (16.7% vs 1.2%), a higher death rate during the follow-up period (14.3% vs 2.4%), and more frequent moderate or severe post kala-azar dermal leishmaniasis (27.3% vs 13.3%). Only 43.5% of the HIV-positive patients were considered cured at 6-months follow-up vs 92.1% of the HIV-negative patients. HIV-positive patients relapsing with VL could become a reservoir of antimonial-resistant Leishmania donovani.
- A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan.
- Authors: Veeken H, Ritmeijer K, Seaman J, Davidson R
- Issue date: 2000 May
- Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
- Authors: Moore E, O'Flaherty D, Heuvelmans H, Seaman J, Veeken H, de Wit S, Davidson RN
- Issue date: 2001
- A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
- Authors: Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN
- Issue date: 2006 Aug 1
- Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable anti-leishmanial drugs: a community-based study.
- Authors: Singh S, Kumar J, Singh R, Dwivedi SN
- Issue date: 2000
- Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
- Authors: Atia AM, Mumina A, Tayler-Smith K, Boulle P, Alcoba G, Elhag MS, Alnour M, Shah S, Chappuis F, van Griensven J, Zachariah R
- Issue date: 2015 Dec